The potential approval of FILSPARI for FSGS by September 2025 could mark a critical milestone, expanding its addressable market and reinforcing its leadership in rare kidney diseases.

Learn about side effects, cost, uses, and more of Filspari (sparsentan), which is a prescription drug that helps manage IgA nephropathy in adults.

FILSPARI (sparsentan) is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a Buy.

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics ...

FILSPARI (sparsentan) FILSPARI (sparsentan) FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data ...

The full approval puts Travere in a better position in its competition with Novartis in the kidney disease IgAN.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation ...

FDA grants full approval to Filspari to slow kidney function decline in adults with primary IgA nephropathy at risk for disease progression.

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Travere Therapeutics, Inc. (NASDAQ: TVTX) today ...